GlaxoSmithKline and Sanofi to Supply EU With 300 Million Covid-19 Doses
August 03 2020 - 2:49AM
Dow Jones News
By Anthony O. Goriainoff
GlaxoSmithKline PLC and Sanofi said on Monday that it is in
advanced discussions with the European Union to supply up to 300
million doses of a Covid-19 vaccine.
The British pharmaceutical giant said the vaccine candidate uses
Sanofi's technology to produce an influenza vaccine, and GSK's
adjuvant technology.
The company said the doses would be manufactured in Europe.
"It has been our steadfast commitment to provide a vaccine that
is affordable and accessible to everyone, and we are grateful to
the European Commission for their ongoing engagement and shared
support of this effort," Sanofi's Executive Vice President Thomas
Triomphe said.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
August 03, 2020 02:34 ET (06:34 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024
